Impaired Vitamin D Metabolism in CKD

Seminars in Nephrology

Volumn 33, Issue 2, 2013, Pages 158-168

  Bosworth, Cortney ^a   De Boer, Ian H ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

1,25 dihydroxyvitamin D; 24,25 dihydroxyvitamin D; Chronic kidney disease; Metabolism; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; COLECALCIFEROL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PARICALCITOL; PLACEBO; VITAMIN D; VITAMIN D DERIVATIVE;

ALBUMINURIA; ARTICLE; CATABOLISM; CHRONIC KIDNEY DISEASE; DIAGNOSTIC TEST; FILTRATION; HEMODIALYSIS; HUMAN; KIDNEY TUBULE ABSORPTION; METABOLIC DISORDER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SECONDARY HYPERPARATHYROIDISM; VITAMIN METABOLISM;

EID: 84875250974     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.12.016     Document Type: Article

References (143)

1. Wolf G. The discovery of vitamin D: the contribution of Adolf Windaus. J Nutr 2004, 134:1299-1302.
2. McCollum E., Simmonds N., Becker J., Shipley P. An experimental demonstration of the existence of a vitamin which promotes calcium deposition. J Biol Chem 1922, 53:293-312.
3. McCollum E.V., Pitz W., Simmonds N., Becker J.E., Shipley P.G., Bunting R.W. The effect of additions of fluorine to the diet of the rat on the quality of the teeth. 1925. Studies on experimental rickets. XXI. An experimental demonstration of the existence of a vitamin which promotes calcium deposition. 1922. The effect of additions of fluorine to the diet of the rat on the quality of the teeth. 1925. J Biol Chem 2002, 277:E8.
4. Brickman A.S., Coburn J.W., Norman A.W. Action of 1,25-dihydroxycholecalciferol, a potent, kidney-produced metabolite of vitamin D, in uremic man. N Engl J Med 1972, 287:891-895.
5. Norman A.W. Evidence for a new kidney-produced hormone, 1,25-dihydroxycholecalciferol, the proposed biologically active form of vitamin D. Am J Clin Nutr 1971, 24:1346-1351.
6. Omdahl J., Holick M., Suda T., Tanaka Y., DeLuca H.F. Biological activity of 1,25-dihydroxycholecalciferol. Biochemistry 1971, 10:2935-2940.
7. Kodicek E., Lawson D.E., Wilson P.W. Biological activity of a polar metabolite of vitamin D. Nature 1970, 228:763-764.
8. Lawson D.E., Fraser D.R., Kodicek E., Morris H.R., Williams D.H. Identification of 1,25-dihydroxycholecalciferol, a new kidney hormone controlling calcium metabolism. Nature 1971, 230:228-230.
9. Slatopolsky E., Weerts C., Thielan J., Horst R., Harter H., Martin K.J. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. J Clin Invest 1984, 74:2136-2143.
10. Andress D.L., Norris K.C., Coburn J.W., Slatopolsky E.A., Sherrard D.J. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989, 321:274-279.
11. Holick M. Vitamin D deficiency. N Engl J Med 2007, 357:266-281.
12. Rosen C.J., Abrams S.A., Aloia J.F., et al. IOM committee members respond to endocrine society vitamin D guideline. J Clin Endocrinol Metab 2012, 97:1146-1152.
13. Dusso A., González E.A., Martin K.J. Vitamin D in chronic kidney disease. Best Pract Res Clin Endocrinol Metab 2011, 25:647-655.
14. Melamed M.L., Thadhani R.I. Vitamin D therapy in chronic kidney disease and end stage renal disease. Clin J Am Soc Nephrol 2012, 7:358-365.
15. Schuster I. Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta 2011, 1814:186-199.
16. McGreevy C., Williams D. New insights about vitamin D and cardiovascular disease: a narrative review. Ann Intern Med 2011, 155:820-826.
17. Van Belle T.L., Gysemans C., Mathieu C. Vitamin D in autoimmune, infectious and allergic diseases: a vital player?. Best Pract Res Clin Endocrinol Metab 2011, 25:617-632.
18. Fleet J.C., DeSmet M., Johnson R., Li Y. Vitamin D and cancer: a review of molecular mechanisms. Biochem J 2012, 441:61-76.
19. Rosen C.J. Clinical practice. Vitamin D insufficiency. N Engl J Med 2011, 364:248-254.
20. Wang T.J., Pencina M.J., Booth S.L., et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008, 117:503-511.
21. Giovannucci E., Liu Y., Hollis B.W., Rimm E.B. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008, 168:1174-1180.
22. de Boer I.H., Kestenbaum B., Shoben A.B., Michos E.D., Sarnak M.J., Siscovick D.S. 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol 2009, 20:1805-1812.
23. Lehmann B., Meurer M. Vitamin D metabolism. Dermatol Ther 2010, 23:2-12.
24. Bikle D.D., Gee E., Halloran B., Kowalski M.A., Ryzen E., Haddad J.G. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab 1986, 63:954-959.
25. Nykjaer A., Dragun D., Walther D., et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999, 96:507-515.
26. Nykjaer A., Fyfe J.C., Kozyraki R., et al. Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D(3). Proc Natl Acad Sci U S A 2001, 98:13895-13900.
27. Bjelakovic G., Gluud L.L., Nikolova D., et al. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 2011, 7. CD007470.
28. Gray R.W., Weber H.P., Dominguez J.H., Lemann J. The metabolism of vitamin D3 and 25-hydroxyvitamin D3 in normal and anephric humans. J Clin Endocrinol Metab 1974, 39:1045-1056.
29. Prosser D.E., Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 2004, 29:664-673.
30. Beckman M.J., Tadikonda P., Werner E., Prahl J., Yamada S., DeLuca H.F. Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme. Biochemistry 1996, 35:8465-8472.
31. Sakaki T., Sawada N., Komai K., et al. Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24. Eur J Biochem 2000, 267:6158-6165.
32. Akiyoshi-Shibata M., Sakaki T., Ohyama Y., Noshiro M., Okuda K., Yabusaki Y. Further oxidation of hydroxycalcidiol by calcidiol 24-hydroxylase. A study with the mature enzyme expressed in Escherichia coli. Eur J Biochem 1994, 224:335-343.
33. Knutson J.C., DeLuca H.F. 25-Hydroxyvitamin D3-24-hydroxylase. Subcellular location and properties. Biochemistry 1974, 13:1543-1548.
34. Annalora A.J., Goodin D.B., Hong W.X., Zhang Q., Johnson E.F., Stout C.D. Crystal structure of CYP24A1, a mitochondrial cytochrome P450 involved in vitamin D metabolism. J Mol Biol 2010, 396:441-451.
35. Jones G., Strugnell S.A., DeLuca H.F. Current understanding of the molecular actions of vitamin D. Physiol Rev 1998, 78:1193-1231.
36. Kumar R., Schaefer J., Grande J.P., Roche P.C. Immunolocalization of calcitriol receptor, 24-hydroxylase cytochrome P-450, and calbindin D28k in human kidney. Am J Physiol 1994, 266:F477-F485.
37. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008, 88:582S-586S.
38. Schlingmann K.P., Kaufmann M., Weber S., et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 2011, 365:410-421.
39. Tebben P.J., Milliner D.S., Horst R.L., et al. Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. J Clin Endocrinol Metab 2012, 97:E423-E427.
40. Gupta R.P., He Y.A., Patrick K.S., Halpert J.R., Bell N.H. CYP3A4 is a vitamin D-24- and 25-hydroxylase: analysis of structure function by site-directed mutagenesis. J Clin Endocrinol Metab 2005, 90:1210-1219.
41. Andersen M.R., Farin F.M., Omiecinski C.J. Quantification of multiple human cytochrome P450 mRNA molecules using competitive reverse transcriptase-PCR. DNA Cell Biol 1998, 17:231-238.
42. Wilkinson G.R. Drug metabolism and variability among patients in drug response. N Engl J Med 2005, 352:2211-2221.
43. Wang Z., Lin Y.S., Zheng X.E., et al. An inducible cytochrome P450 3A4-dependent vitamin D catabolic pathway. Mol Pharmacol 2012, 81:498-509.
44. Outila T.A., Mattila P.H., Piironen V.I., Lamberg-Allardt C.J. Bioavailability of vitamin D from wild edible mushrooms (Cantharellus tubaeformis) as measured with a human bioassay. Am J Clin Nutr 1999, 69:95-98.
45. Eisman J.A., DeLuca H.F. Intestinal 1,25-dihydroxyvitamin D3 binding protein: specificity of binding. Steroids 1977, 30:245-257.
46. Deluca H.F., Prahl J.M., Plum L.A. 1,25-Dihydroxyvitamin D is not responsible for toxicity caused by vitamin D or 25-hydroxyvitamin D. Arch Biochem Biophys 2011, 505:226-230.
47. Takeyama K., Kato S. The vitamin D3 1alpha-hydroxylase gene and its regulation by active vitamin D3. Biosci Biotechnol Biochem 2011, 75:208-213.
48. Kim M.S., Kondo T., Takada I., et al. DNA demethylation in hormone-induced transcriptional derepression. Nature 2009, 461:1007-1012.
49. Zierold C., Mings J.A., DeLuca H.F. Regulation of 25-hydroxyvitamin D3-24-hydroxylase mRNA by 1,25-dihydroxyvitamin D3 and parathyroid hormone. J Cell Biochem 2003, 88:234-237.
50. Jones G., Prosser D.E., Kaufmann M. 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch Biochem Biophys 2012, 523:9-18.
51. Dusso A.S., Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Kidney Int 2011, 79:715-729.
52. Huening M., Yehia G., Molina C.A., Christakos S. Evidence for a regulatory role of inducible cAMP early repressor in protein kinase a-mediated enhancement of vitamin D receptor expression and modulation of hormone action. Mol Endocrinol 2002, 16:2052-2064.
53. Armbrecht H.J., Hodam T.L., Boltz M.A., Partridge N.C., Brown A.J., Kumar V.B. Induction of the vitamin D 24-hydroxylase (CYP24) by 1,25-dihydroxyvitamin D3 is regulated by parathyroid hormone in UMR106 osteoblastic cells. Endocrinology 1998, 139:3375-3381.
54. Shimada T., Hasegawa H., Yamazaki Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004, 19:429-435.
55. Yamashita T., Yoshioka M., Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000, 277:494-498.
56. Shimada T., Mizutani S., Muto T., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001, 98:6500-6505.
57. Strewler G.J. FGF23, hypophosphatemia, and rickets: has phosphatonin been found?. Proc Natl Acad Sci U S A 2001, 98:5945-5946.
58. Tsujikawa H., Kurotaki Y., Fujimori T., Fukuda K., Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003, 17:2393-2403.
59. Perwad F., Portale A.A. Vitamin D metabolism in the kidney: regulation by phosphorus and fibroblast growth factor 23. Mol Cell Endocrinol 2011, 347:17-24.
60. Wu S., Grieff M., Brown A.J. Regulation of renal vitamin D-24-hydroxylase by phosphate: effects of hypophysectomy, growth hormone and insulin-like growth factor I. Biochem Biophys Res Commun 1997, 233:813-817.
61. Krajisnik T., Björklund P., Marsell R., et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007, 195:125-131.
62. Quarles L.D. Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res 2012, 318:1040-1048.
63. Medici D., Razzaque M.S., Deluca S., et al. FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis. J Cell Biol 2008, 182:459-465.
64. Faul C., Amaral A.P., Oskouei B., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121:4393-4408.
65. Shimamura Y., Hamada K., Inoue K., et al. Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. Clin Exp Nephrol 2012, 16:722-729.
66. Yoshida T., Fujimori T., Nabeshima Y. Mediation of unusually high concentrations of 1,25-dihydroxyvitamin D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase gene. Endocrinology 2002, 143:683-689.
67. Hu M.C., Shi M., Zhang J., et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010, 24:3438-3450.
68. Akeno N., Saikatsu S., Kawane T., Horiuchi N. Mouse vitamin D-24-hydroxylase: molecular cloning, tissue distribution, and transcriptional regulation by 1alpha,25-dihydroxyvitamin D3. Endocrinology 1997, 138:2233-2240.
69. Safadi F.F., Thornton P., Magiera H., et al. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest 1999, 103:239-251.
70. Zella L.A., Shevde N.K., Hollis B.W., Cooke N.E., Pike J.W. Vitamin D-binding protein influences total circulating levels of 1,25-dihydroxyvitamin D3 but does not directly modulate the bioactive levels of the hormone in vivo. Endocrinology 2008, 149:3656-3667.
71. Bhan I., Powe C.E., Berg A.H., et al. Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int 2012, 82:84-89.
72. Powe C.E., Ricciardi C., Berg A.H., et al. Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res 2011, 26:1609-1616.
73. Cui S., Verroust P.J., Moestrup S.K., Christensen E.I. Megalin/gp330 mediates uptake of albumin in renal proximal tubule. Am J Physiol 1996, 271:F900-F907.
74. Dusso A., Lopez-Hilker S., Lewis-Finch J., et al. Metabolic clearance rate and production rate of calcitriol in uremia. Kidney Int 1989, 35:860-864.
75. Gray R., Boyle I., DeLuca H.F. Vitamin D metabolism: the role of kidney tissue. Science 1971, 172:1232-1234.
76. Fraser D.R., Kodicek E. Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature 1970, 228:764-766.
77. Hasegawa H., Nagano N., Urakawa I., et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010, 78:975-980.
78. Levin A., Bakris G.L., Molitch M., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007, 71:31-38.
79. Lee S.W., Russell J., Avioli L.V. 25-hydroxycholecalciferol to 1,25-dihydroxycholecalciferol: conversion impaired by systemic metabolic acidosis. Science 1977, 195:994-996.
80. Hsu C.H., Patel S.R., Young E.W., Vanholder R. Effects of purine derivatives on calcitriol metabolism in rats. Am J Physiol 1991, 260:F596-F601.
81. Vanholder R., Patel S., Hsu C.H. Effect of uric acid on plasma levels of 1,25(OH)2D in renal failure. J Am Soc Nephrol 1993, 4:1035-1038.
82. Takemoto F., Shinki T., Yokoyama K., et al. Gene expression of vitamin D hydroxylase and megalin in the remnant kidney of nephrectomized rats. Kidney Int 2003, 64:414-420.
83. Helvig C.F., Cuerrier D., Hosfield C.M., et al. Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int 2010, 78:463-472.
84. Zehnder D., Quinkler M., Eardley K.S., et al. Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int 2008, 74:1343-1353.
85. Rock C.L., Emond J.A., Flatt S.W., et al. Weight loss is associated with increased serum 25-hydroxyvitamin D in overweight or obese women. Obesity (Silver Spring) 2012, 20:2296-2301.
86. Bertrand K.A., Giovannucci E., Liu Y., et al. Determinants of plasma 25-hydroxyvitamin D and development of prediction models in three US cohorts. Br J Nutr 2012, 108:1889-1896.
87. Jacob A.I., Sallman A., Santiz Z., Hollis B.W. Defective photoproduction of cholecalciferol in normal and uremic humans. J Nutr 1984, 114:1313-1319.
88. Thrailkill K.M., Jo C.H., Cockrell G.E., Moreau C.S., Fowlkes J.L. Enhanced excretion of vitamin D binding protein in type 1 diabetes: a role in vitamin D deficiency?. J Clin Endocrinol Metab 2011, 96:142-149.
89. Colston K., Williams N.J., Cleeve H.J. Studies on vitamin D binding protein in the nephrotic syndrome. Clin Chem 1985, 31:718-721.
90. Petkovich M., Jones G. CYP24A1 and kidney disease. Curr Opin Nephrol Hypertens 2011, 20:337-344.
91. Quarles L.D. The bone and beyond: 'Dem bones' are made for more than walking. Nat Med 2011, 17:428-430.
92. Horst R.L., Littledike E.T., Gray R.W., Napoli J.L. Impaired 24,25-dihydroxyvitamin D production in anephric human and pig. J Clin Invest 1981, 67:274-280.
93. Hsu C.H., Patel S., Buchsbaum B.L. Calcitriol metabolism in patients with chronic renal failure. Am J Kidney Dis 1991, 17:185-190.
94. Leeuwenkamp O., van der Wiel H., Lips P., et al. Human pharmacokinetics of orally administered (24 R)-hydroxycalcidiol. Eur J Clin Chem Clin Biochem 1993, 31:419-426.
95. Haddad J.G., Min C., Mendelsohn M., Slatopolsky E., Hahn T.J. Competitive protein-binding radioassay of 24,25-dihydroxyvitamin D in sera from normal and anephric subjects. Arch Biochem Biophys 1977, 182:390-395.
96. Zerwekh J.E., McPhaul J.J., Parker T.F., Pak C.Y. Extra-renal production of 24,25-dihydroxyvitamin D in chronic renal failure during 25 hydroxyvitamin D3 therapy. Kidney Int 1983, 23:401-406.
97. Weisman Y., Eisenberg Z., Leib L., Harell A., Shasha S.M., Edelstein S. Serum concentrations of 24,25-dihydroxy vitamin D in different degrees of chronic renal failure. Br Med J 1980, 281:712-713.
98. Koenig K.G., Lindberg J.S., Zerwekh J.E., Padalino P.K., Cushner H.M., Copley J.B. Free and total 1,25-dihydroxyvitamin D levels in subjects with renal disease. Kidney Int 1992, 41:161-165.
99. Ishimura E., Nishizawa Y., Inaba M., et al. Serum levels of 1,25-dihydroxyvitamin D, 24,25-dihydroxyvitamin D, and 25-hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int 1999, 55:1019-1027.
100. Strathmann F.G., Laha T.J., Hoofnagle A.N. Quantification of 1{alpha},25-dihydroxy vitamin D by immunoextraction and liquid chromatography/tandem mass spectrometry. Clin Chem 2011, 57:1279-1285.
101. Bosworth C., Levin G., Robinson-Cohen C., et al. The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease. Kidney Int 2012, 82(6):693-700.
102. Dai B., David V., Alshayeb H.M., Showkat A., Gyamlani G., Horst R.L., Wall B.M., Quarles L.D. Assessment of 24,25(OH)2D levels does not support FGF-23-mediated catabolism of vitamin D metabolites. Kidney Int 2012, 82:1061-1070.
103. Granata S., Zaza G., Simone S., et al. Mitochondrial dysregulation and oxidative stress in patients with chronic kidney disease. BMC Genomics 2009, 10:388.
104. Michaud J., Nolin T.D., Naud J., et al. Effect of hemodialysis on hepatic cytochrome P450 functional expression. J Pharmacol Sci 2008, 108:157-163.
105. Sun D.F., Zheng Z., Tummala P., Oh J., Schaefer F., Rabkin R. Chronic uremia attenuates growth hormone-induced signal transduction in skeletal muscle. J Am Soc Nephrol 2004, 15:2630-2636.
106. Hruska K.A., Mathew S., Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res 2005, 97:105-114.
107. Dietary Reference Intakes for Calcium and Vitamin D 2011, The National Academies Press, Washington, DC, Committee to Review Dietary Reference Intakes for Vitamin D and Calcium; Institute of Medicine. A.C. Ross, C.L. Taylor, A.L. Yaktine, H.B. Del Valle (Eds.).
108. Holick M. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 2009, 19:73-78.
109. González E.A., Sachdeva A., Oliver D.A., Martin K.J. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004, 24:503-510.
110. Blair D., Byham-Gray L., Lewis E., McCaffrey S. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. J Ren Nutr 2008, 18:375-382.
111. LaClair R.E., Hellman R.N., Karp S.L., et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005, 45:1026-1033.
112. Bhan I., Burnett-Bowie S.A., Ye J., Tonelli M., Thadhani R. Clinical measures identify vitamin D deficiency in dialysis. Clin J Am Soc Nephrol 2010, 5:460-467.
113. Pietrek J., Kokot F. Serum 25-hydroxyvitamin D in patients with chronic renal disease. Eur J Clin Invest 1977, 7:283-287.
114. Ravani P., Malberti F., Tripepi G., et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009, 75:88-95.
115. Chonchol M., Scragg R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int 2007, 71:134-139.
116. Wang T.J., Zhang F., Richards J.B., et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010, 376:180-188.
117. Palmer S.C., McGregor D.O., Macaskill P., Craig J.C., Elder G.J., Strippoli G.F. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2007, 147:840-853.
118. Silver J., Naveh-Many T., Mayer H., Schmelzer H.J., Popovtzer M.M. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 1986, 78:1296-1301.
119. Russell J., Lettieri D., Sherwood L.M. Suppression by 1,25(OH)2D3 of transcription of the pre-proparathyroid hormone gene. Endocrinology 1986, 119:2864-2866.
120. Gutierrez O.M., Mannstadt M., Isakova T., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008, 359:584-592.
121. Ix J.H., Shlipak M.G., Wassel C.L., Whooley M.A. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant 2010, 25:993-997.
122. Kendrick J., Cheung A.K., Kaufman J.S., et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011, 22:1913-1922.
123. Isakova T., Xie H., Yang W., et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011, 305:2432-2439.
124. Slatopolsky E., Brown A., Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 1999, 73:S14-S19.
125. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009, 113:S1-S130. Group KDIGOKC-MW.
126. Shoben A.B., Rudser K.D., de Boer I.H., Young B., Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008, 19:1613-1619.
127. Teng M., Wolf M., Ofsthun M.N., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005, 16:1115-1125.
128. Tentori F., Hunt W.C., Stidley C.A., et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006, 70:1858-1865.
129. Shoji T., Shinohara K., Kimoto E., et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004, 19:179-184.
130. Kalantar-Zadeh K., Kuwae N., Regidor D.L., et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006, 70:771-780.
131. Kovesdy C.P., Ahmadzadeh S., Anderson J.E., Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008, 168:397-403.
132. de Zeeuw D., Agarwal R., Amdahl M., et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010, 376:1543-1551.
133. Thadhani R., Appelbaum E., Pritchett Y., et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012, 307:674-684.
134. Liu S., Tang W., Zhou J., et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006, 17:1305-1315.
135. de Boer I.H., Levin G., Robinson-Cohen C., et al. Serum 25-hydroxyvitamin D concentration and risk for major clinical disease events in a community-based population of older adults: a cohort study. Ann Intern Med 2012, 156:627-634.
136. Autier P., Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007, 167:1730-1737.
137. Bosworth C., de Boer I.H., Targher G., Kendrick J., Smits G., Chonchol M. The effect of combined calcium and cholecalciferol supplemenation on bone mineral density in elderly women with moderate chronic kidney disease. Clin Nephrol 2012 May, 77(5):358-365.
138. Stubbs J.R., Idiculla A., Slusser J., Menard R., Quarles L.D. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 2010, 21:353-361.
139. Jean G., Terrat J.C., Vanel T., et al. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment. Nephron Clin Pract 2008, 110:c58-c65.
140. Matias P.J., Jorge C., Ferreira C., et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 2010, 5:905-911.
141. Manson J.E., Bassuk S.S., Lee I.M., et al. The VITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 2012, 33:159-171.
142. Muindi J.R., Yu W.D., Ma Y., et al. CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology 2010, 151:4301-4312.
143. Chiellini G., Rapposelli S., Zhu J., et al. Synthesis and biological activities of vitamin D-like inhibitors of CYP24 hydroxylase. Steroids 2012, 77:212-223.